Available Prescribing Info
- Annotation of FDA Label for hydralazine and NAT2
- Annotation of FDA Label for isoniazid,pyrazinamide,rifampin and NAT2
- Annotation of PMDA Label for isoniazid and NAT2
Hydralazine hydrochloride and isosorbide dinitrate (Bidil) is metabolized by acetylation, and individuals who are 'fast acetylators' may have increased exposure to the drug, whereas individuals who are 'slow acetylators' may have increased drug bioavailability. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene.
There's more of this label. Read more.
'Slow inactivators' of isoniazid may be more susceptible to drug toxicity when taking Rifator due to higher blood concentrations of the drug in these individuals. Acetylation status of an individual can be determined by examining genetic variants in the NAT2 gene.
There's more of this label. Read more.
The PMDA package insert for isoniazid (ISCOTIN) notes that acetylation rate of isoniazid differs between individuals, and that about 10% of Japanese are slow acetylators.
There's more of this label. Read more.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
|Alternate Names ?||Chemicals ?||
(+ chr strand)
|rs1041983||NC_000008.10:g.18257795C>T, NC_000008.11:g.18400285C>T, NG_012246.1:g.14041C>T, NM_000015.2:c.282C>T, NP_000006.2:p.Tyr94=, XM_011544358.1:c.282C>T, XP_011542660.1:p.Tyr94=, rs17845484, rs17858364, rs59855457||
C > T
|rs1208||NC_000008.10:g.18258316G=, NC_000008.10:g.18258316G>A, NC_000008.11:g.18400806G=, NC_000008.11:g.18400806G>A, NG_012246.1:g.14562G=, NG_012246.1:g.14562G>A, NM_000015.2:c.803G=, NM_000015.2:c.803G>A, NP_000006.2:p.Arg268=, NP_000006.2:p.Arg268Lys, XM_011544358.1:c.803G=, XM_011544358.1:c.803G>A, XP_011542660.1:p.Arg268=, XP_011542660.1:p.Arg268Lys, rs17126586, rs17845485, rs17858365, rs3181478, rs52821724, rs56599719, rs58999469||
G > A
|rs1495741||NC_000008.10:g.18272881G>A, NC_000008.11:g.18415371G>A, rs57451543||
G > A
|rs1799929||NC_000008.10:g.18257994C>T, NC_000008.11:g.18400484C>T, NG_012246.1:g.14240C>T, NM_000015.2:c.481C>T, NP_000006.2:p.Leu161=, XM_011544358.1:c.481C>T, XP_011542660.1:p.Leu161=, rs17595342, rs4646268, rs58882350, rs60310310||
C > T
|rs1799930||NC_000008.10:g.18258103G>A, NC_000008.11:g.18400593G>A, NG_012246.1:g.14349G>A, NM_000015.2:c.590G>A, NP_000006.2:p.Arg197Gln, XM_011544358.1:c.590G>A, XP_011542660.1:p.Arg197Gln, rs17517027, rs17856496, rs4646269, rs60190029, rs61467963||
G > A
|rs1799931||NC_000008.10:g.18258370G>A, NC_000008.11:g.18400860G>A, NG_012246.1:g.14616G>A, NM_000015.2:c.857G>A, NP_000006.2:p.Gly286Glu, XM_011544358.1:c.857G>A, XP_011542660.1:p.Gly286Glu, rs17693862, rs4646270, rs52802193, rs58803786||
G > A
|rs1801279||NC_000008.10:g.18257704G>A, NC_000008.11:g.18400194G>A, NG_012246.1:g.13950G>A, NM_000015.2:c.191G>A, NP_000006.2:p.Arg64Gln, XM_011544358.1:c.191G>A, XP_011542660.1:p.Arg64Gln, rs17126583, rs4134723, rs52824535||
G > A
|rs1801280||NC_000008.10:g.18257854T>C, NC_000008.11:g.18400344T>C, NG_012246.1:g.14100T>C, NM_000015.2:c.341T>C, NP_000006.2:p.Ile114Thr, XM_011544358.1:c.341T>C, XP_011542660.1:p.Ile114Thr, rs4134724, rs56935242||
T > C
|rs4271002||NC_000008.10:g.18248268G>C, NC_000008.11:g.18390758G>C, NG_012246.1:g.4514G>C, NM_000015.2:c.-594G>C, XM_011544358.1:c.-1985G>C, rs17642704||
G > C
|rs45607939||NC_000008.10:g.18258126A>T, NC_000008.11:g.18400616A>T, NG_012246.1:g.14372A>T, NM_000015.2:c.613A>T, NP_000006.2:p.Met205Leu, XM_011544358.1:c.613A>T, XP_011542660.1:p.Met205Leu||
A > T
|rs4646244||NC_000008.10:g.18247718T>A, NC_000008.11:g.18390208T>A, NG_012246.1:g.3964T>A, NM_000015.2:c.-1144T>A, rs17595300||
T > A
|rs4646267||NC_000008.10:g.18247913A>G, NC_000008.11:g.18390403A>G, NG_012246.1:g.4159A>G, NM_000015.2:c.-949A>G||
A > G
|PharmGKB Accession Id:||PA18|
|Cytogenetic Location:||chr8 : p22 - p22|
|GP mRNA Boundary†:||chr8 : 18248755 - 18258723|
|GP Gene Boundary†:||chr8 : 18238755 - 18261723|
UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.View on UCSC Browser
Function and expression
Arylamine N-acetyltransferases (NATs) are xenobiotic metabolizing enzymes for which three distinct enzymatic activities have been described. The first (EC 184.108.40.206) involves the acetyl coenzyme A (CoA) dependent N-acetylation of arylamines and arylhydrazines, a reaction usually associated with xenobiotic detoxification. The second (EC 220.127.116.11) is also acetyl-CoA dependent and involves O-acetylation of N-hydroxyarylamines [Article:19379125], typically generated through N-oxidation of arylamines by cytochrome P450 enzymes. The third (EC 18.104.22.168) is an acetyl-CoA independent N,O-acetyltransfer performed on N-arylhydroxamic acids, generating highly reactive mutagenic compounds that bind to DNA. NATs have important roles in the metabolism and detoxification of xenobiotics and therapeutic drugs, and are implicated in cancer risk due to their role in the activation or detoxification of carcinogens and their interaction with environmental chemicals [Articles:19018723, 22776642, 18852012].
Two NAT genes (NAT1 and NAT2) have been characterized in humans, which differ in gene structure, extent of genetic variation, pattern of developmental and tissue expression [Articles:23497148, 24467436, 18680469]. Their protein products have different physiological roles, and despite being structurally similar, differences in key residues result in different substrate profiles/ affinities [Articles:23497148, 24467436, 18680466]. NAT1 is ubiquitously expressed, and therefore may be involved in homeostasis and development, though levels of expression vary between cell types and tissues [Articles:19018723, 21401512, 17392017, 22090474, 18680469]. NAT2 expression is found predominantly in the liver, small intestine and colon tissues and thus is regarded as a typical xenobiotic metabolizing enzyme [Articles:17287389, 19018723, 21401512, 22090474, 18680469], though basal NAT2 mRNA levels can be found in most tissues [Article:19379125].
Genomic locus organization and protein structure
The genes NAT1, NAT2 and the nonfunctional pseudogene NATP (AACP) are found on chromosome 8p22 [Articles:19018723, 2340091, 8110178, 19379125]. NAT1 and NAT2 share 87.5% coding sequence homology, and around 80% with the corresponding sequence in NATP [Article:2340091]. The NAT1 gene contains eight non-coding exons upstream of the intronless open reading frame (ORF), resulting in differentially spliced transcripts with the same coding region that can be found in different tissues [Articles:15487985, 15853926, 15226672]. The NAT2 gene has one non-coding exon around 8.6kb upstream of the intronless ORF [Articles:15853926, 17287389, 1676262]. The two genes have ORFs of 870 nucleotides in length and they encode similar size proteins of 290 amino acids (~30 kDa) (GENEID: 9 and GENEID: 10). The crystal structure of human NAT1 and NAT2 proteins, 3-dimensional modeling and docking simulations, have provided insight into the functional properties of the two different isoenzymes, revealing a larger substrate binding pocket with a lip in NAT2 compared to NAT1, likely contributing to different substrate specificities [Articles:17656365, 18680466].
Genetic Polymorphisms and phenotype
Both NAT1 and NAT2 are polymorphic genes - to date (Jan 2014) 28 NAT1 alleles and 88 NAT2 alleles have been assigned official symbols by the Arylamine N-acetyltransferase Gene Nomenclature Committee, according to consensus guidelines [Article:18334921] (background). NAT1*4 and NAT2*4 are the reference (or "wildtype") alleles for the respective genes, and most variant alleles differ from these by one or more single nucleotide polymorphisms (SNPs).
Many NAT1 alleles result in a phenotype equivalent to that of reference NAT1*4 (*20, *21, *23, *24, *25, *27), some confer a "slow" acetylation phenotype (*14A, *14B, *17, *22), or result in truncated proteins with no enzymatic activity (*15, *19A, *19B), and others are undetermined. Despite these polymorphisms, looking across global human populations the NAT1 sequence seems to be highly conserved, though variation in the 3'-untranslated region (3'UTR) has been maintained [Articles:16416399, 21995608, 21081654].
In contrast, the NAT2 gene has a high frequency of functional variation, differing amongst populations that are ethnically diverse, and has high levels of haplotype diversity [Articles:16416399, 21995608]. SNPs within the NAT2 gene can affect NAT2 function by resulting in reduced enzyme stability, altered affinity for substrate, or a protein that is targeted for proteosome degradation [Articles:18680467, 19379125]. NAT2 genotypes can be grouped into three different phenotypes: "slow acetylator" (two slow alleles), "intermediate acetylator" (1 slow and 1 rapid allele), and "rapid" acetylator (2 rapid alleles, sometimes referred to as "fast") [Article:19018723]. Some papers simply report rapid (any genotypes containing NAT2*4) and slow (any non-carriers of NAT2*4) acetylators (for example [Article:17335581]). However, rapid alleles additional to NAT2*4 have been identified recently (e.g. *11A, *12A-C, *13A, *18), and heterozygous (intermediate) genotypes seem to display differences in phenotype compared to homozygous rapid (for examples see Section 4. Caffeine below). In addition, within the slow acetylator genotype group there is heterogeneity in phenotype due to variation in enzyme activity conferred by different alleles [Articles:22970273, 19379125, 7627960, 10335449] , which may affect the ability to detect significant associations [Article:24221535].
Early studies report a bimodal pattern of drug acetylation in a given population, and sulfamethazine (SMZ) was described as a suitable probe drug to divide individuals into a slow or rapid acetylator phenotype by plotting serum, urine or liver cytosol acetylation percentages [Articles:5365949, 7273597, 4029245, 2312737]. Now, many studies genotype NAT2 variants to define acetylator phenotype instead, and the SNPs investigated can vary between studies. An economic 4-SNP genotyping panel was reported to accurately predict NAT2 acetylator phenotype in different populations; rs1801280, rs1799930, rs1799931 and rs1801279 (See Variant Summaries) [Articles:22092036, 22676187] Hein & Doll Letter in response. Early genotyping methods based on PCR-RFLP typically used Kpn I (cuts wildtype allele C at position 481 rs1799929), Taq 1 (cuts wildtype allele G at position 590 rs1799930) and BamH I (cuts wildtype allele G at position 857 rs1799931) enzymes to distinguish NAT2*4 from the slow alleles described as *5, *6 and *7, respectively (for example [Articles:21261721, 12668988]) or defined as *5B, *6A, and *7B, respectively (for example [Articles:21856096, 21753138]). However, such approaches may lead to misclassification as the three SNPs they detect are present in numerous NAT2* alleles (see Variant Summaries). The methodology is also unable to detect other NAT2 slow alleles, such as NAT2*14A and *14B.
Several studies examining the diversity of NAT2 haplotypes between different populations and ethnicities support the hypothesis suggesting the NAT2 slow acetylator phenotype was positively selected for in the transition to an agricultural/ pastoral lifestyle from a hunter-gatherer/ nomadic lifestyle, resulting in changes in diet and thus exposure to different xenobiotics [Articles:16786516, 18043717, 18304320, 18773084, 21494681, 16416399]. For example, slow acetylator status is higher amongst Tajik populations (agriculturists) compared to Kirghiz populations (nomads) in Central Asia [Article:18043717], and a high frequency of rapid or intermediate status is observed in hunter-gatherer populations in Western/ Southern Africa (Kung San, Bakola Pygmy, Biaka Pygmy populations) [Articles:16786516, 21995608]. In India, the frequency of slow acetylators (based on genotype) is higher than rapid acetylators in areas where a vegetarian diet dominates, and the converse is observed in areas where non-vegetarian diet is more frequent [Article:23394391]. Worldwide NAT2 allele frequencies are detailed in the individual Variant Summaries (see links below).
It should be noted that the phenotype associated with a particular variant or allele may be specific to particular drugs, and that the designated phenotypes of NAT1 and NAT2 alleles are not always consistent in all studies (discussed in detail in [Article:18680467]). For example, compared with the product of the NAT1*4 reference allele, the enzyme conferred by NAT1*11 (as determined by genotyping 445G>A, 459G>A, 640T>G) displays increased acetylation activity against p-aminobenzoic acid. However, this effect seems to be substrate specific, as the difference in activity is not statistically significant with the carcinogen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) [Article:17909564]. Other studies report contradicting results (as discussed in [Article:17909564]). Another example of inconsistent phenotype is seen with the NAT2*7 signature variant rs1799931 857G>A, which displays decreased N-acetylation of sulfamethazine (SMZ) and decreased O-acetylation of the carcinogen N-OH-4-aminobiphenyl in vitro, indicating a slow acetylator phenotype. However O-acetylation activity against N-OH-PhIP does not differ from NAT2 4 [Article:17434923]. These results are also reflected in cells which express the NAT2*7B allele (rs1799931 857G>A and rs1041983 282C>T) [Article:17434923]. Regulatory mechanisms, substrate interaction, exposure to xenobiotics and other environmental factors may also influence NAT1 and NAT2 allele expression and activity [Articles:18680469, 18680470].
Another issue is determining phenotype from genotype. NAT2 alleles are often reported by examining a single SNP, however genotyping for other positions is required to confirm that it is the only variant in order to rule out other positions, and the number of SNPs covered by studies differs (also discussed in [Article:18680468]. This is particularly important for SNPs that are in NAT2 alleles with different phenotypes; for example rs1799929 allele T (the signature SNP for NAT2*11) is present in several slow and rapid alleles but alone does not seem to affect acetylation activity (see Variant Summaries) [Article:17434923].
Below we describe some of the important pharmacogenetic associations between NAT1 and NAT2 genetic variants and drug response, arranged by drug indication. Pharmacogenetic associations between NAT polymorphisms and drug responses are predominantly described for NAT2, because of its role in the metabolism of numerous pharmaceuticals. Please note that some studies do not mention NAT genotyping or the specific NAT enzyme involved in metabolism, simply reporting acetylation phenotype. However, where possible, we provide specific details for studies that do describe the specific enzyme or genetic variant.
1. Anti-infective agents
1.1 Isoniazid (INH)
The vast majority of NAT2 pharmacogenetic studies are those that report an association (or lack of) with anti-tuberculosis (anti-TB) drug-induced hepatotoxicity (ATDH), liver injury (DILI), or hepatitis. Standard therapy for TB infection involves a treatment regimen of INH, pyrazinamide, and rifampicin, sometimes with ethambutol or streptomycin, for 2 months, then INH and rifampicin for an additional 4 months [Articles:16503745, 17995946]. Latent infections can be treated with INH alone [Article:16503745]. NAT2 has a major role in the metabolism of INH, mediating its biotransformation to the metabolite acetyl-INH, which is hydrolyzed to isonicotinic acid or acetyl-hydrazine [Articles:18220565, 17995946, 21412230, 22037847, 21913872]. Acetyl-hydrazine can be further acetylated to the non-toxic diacetylhydrazine, or hydrolyzed to hydrazine [Articles:18220565, 17995946, 21412230, 22037847, 21913872]. Liver toxicity of INH treatment derives from INH itself (a hydrazine derivative) and its metabolites, including acetyl-hydrazine, hydrazine and ammonia, and is thought to involve the formation of reactive oxygen species that can cause necrosis and autoimmunity [Articles:21412230, 17995946, 18544910, 18220565, 1149365] and may also involve epigenetic effects [Article:17156885].
Due to reduced metabolism, NAT2 slow acetylators have increased exposure to INH and hydrazine compared to rapid acetylators [Articles:18544910, 17021358, 24383060, 23091716, 22695364, 24492365]. NAT2 slow acetylator profile (or two slow NAT2 alleles) has therefore been associated with an increased risk of hepatotoxicity/ liver injury/ hepatitis induced by anti-TB drug treatment as compared to rapid acetylators (and sometimes intermediates) in many studies [Articles:18421452, 17950035, 20392357, 22012226, 23190413, 22020825, 21047300, 18330759, 23407048, 10751073, 11915035, 12668988, 16246623, 21261721, 22162992, 22506592, 21753138, 21856096, 22788240, 23875638, 23394127]. Individual NAT2 SNPs have also been associated with ATDH (see Variant Summaries below).
However, there are numerous contradictory studies that do not find an association between increased risk of ATDH and slow NAT2 acetylator genotype in TB patients [Articles:19761367, 22947533, 22283902, 16677176, 16770646, 21753138], or NAT2 genotype with INH-induced adverse reactions in healthy individuals, despite an association seen between genotype and acetylator phenotype [Article:21479500]. Meta-analyses suggest there is a significantly increased risk of anti-TB drug induced liver injury/ hepatotoxicity in NAT2 slow acetylators [Articles:23082213, 23277397, 18713495, 22409928], but a publication bias for positive results in smaller studies is reported [Articles:23082213, 23277397]. This, along with allele frequency, definition of hepatotoxicity, study exclusion criteria, drug combination, other genetic variants, population ethnicity, genotyping method, haplotype reconstruction/ allele definition method, and grouping of genotypes into acetylator status, are all factors that may contribute to the differences seen in study outcome.
Despite these inconsistencies, a recent randomized control trial that compared standard INH dosing (n=52) with pharmacogenetic-based dosing (n=47) in Japanese patients supports an association between acetylator status (determined by NAT2 genotype) and INH treatment outcome. A significant decrease in the incidence of DILI in slow-acetylators and a reduced incidence of persistent positive TB culture (indicating efficacy) in rapid acetylators was observed compared to the corresponding genotype groups on standard dose [Article:23150149]. Combined, the relative risk of unfavorable events was significantly lower in the pharmacogenetic-based treatment group compared to the standard treatment group, suggesting that NAT2-based dosing may be of clinical relevance to enhance INH treatment efficacy and reduce toxicity, though further and more extensive studies in other populations are required [Article:23150149].
FDA-approved drug labels for INH differ slightly between manufacturers. One does not directly mention the NAT2 gene, but does mention that slow acetylation may result in higher levels of the drug and therefore an increase in toxic reactions (Remedyrepack Inc). Another mentions that rate of acetylation is genetically determined, different ethnicities display differences in rate of inactivation, and that slow acetylation may result in higher blood levels of the drug and therefore an increase in toxic reactions (Mikart Inc.). Rifater drug labels (a combination of rifampin, INH, pyrazinamide) contain similar information. All labels contain a boxed warning regarding hepatitis associated with INH treatment, but none mention this with regard to NAT2 or genetic testing.
Sulfamethoxazole is acetylated to N-acetylsulfamethoxazole, or oxidized to sulfamethoxazole hydroxylamine (a reactive metabolite which may result in toxicity) by CYP450 enzymes [Article:18190954]. Recent studies have shown an association between NAT2 genotypes and sulfamethoxazole pharmacokinetics (PK). In renal transplant patients treated with an immunosuppressive regimen, significantly higher sulfamethoxazole concentrations in slow acetylators (defined as homozygotes or compound heterozygotes for NAT2*5, *6, or *7 variants) are seen compared to rapid acetylators (homozygous NAT2*4/*4), though the clinical relevance of this is not clear as toxic side effects in this study were not observed [Article:22106207].
Pneumocystis fungi is commonly found in the respiratory tract of most healthy individuals; however it can cause pneumonia in those who are immune-compromised or receiving immunosuppressive drugs, and is one of the most common infections associated with acquired immunodeficiency syndrome (AIDS) in HIV-infected patients [Article:22167405]. Co-trimoxazole (sulfamethoxazole combined with trimethoprim) is the choice medication for prophylaxis and treatment of Pneumocystis pneumonia; however it is associated with several significant side effects including skin rash, Stevens-Johnson syndrome and hepatic impairment [Article:22167405]. Different rates of co-trimoxazole induced adverse reactions are reported between ethnicities/ races (higher in Caucasians/ White patients), indicating a possible underlying pharmacogenetic association [Articles:8686712, 10509585]. Susceptibility to toxicity has been investigated in relation to NAT2 genotype due to the role of NAT2 in sulfamethoxazole PK. In a study of 48 Caucasian children under 3 years of age, 60% developed adverse reactions when treated with co-trimoxazole for pneumonia infection [Article:9923584]. NAT2 variants rs1799930 allele A and rs1799931 allele A were independently found at a significantly higher frequency in children with co-trimoxazole-induced adverse drug reactions (ADRs) compared to those without. Conversely, a significantly higher number of children with no variant alleles were found in the group without ADRs (absence of variant alleles rs1799929 481T, rs1208 803G, rs1799930 590A, rs1799931 857A) [Article:9923584]. In systemic lupus erythematosus (SLE) patients in Japan who were treated with co-trimoxazole, slow acetylator status (determined in this study by NAT2 genotypes *6A/*6A, *6A/*7B, *7B/*7B) was associated with an increased risk of adverse events, compared to rapid acetylators (genotypes NAT2*4/*4, *4/*5B, *4/*5E, *4/*6A, *4/*7B) [Article:17335581]. However, when sequencing the NAT2 gene, a matched case-control study excluding immuno-compromised patients found no association with individual NAT2 variants or slow acetylator genotype and risk of hypersensitivity to co-trimoxazole [Article:22850190]. Some adverse reactions with underlying auto-immune responses are not concentration-dependent, for example carbamazepine-induced Stevens Johnson Syndrome for which individuals with the HLA-B*5201 allele are at high risk [Article:23695185]. This may therefore be a factor underlying the lack of association between NAT2 genotype and hypersensitivity to co-trimoxazole.
Side effects of co-trimoxazole are higher in those with HIV infection compared to those without [Article:18190954] (Septra drug label), though association with NAT2 acetylator status and toxicity in HIV patients has been inconsistent. In the majority of studies, no association with co-trimoxazole hypersensitivity (fever and/ or rash, including Stevens-Johnson syndrome) and NAT2 slow acetylator genotype or individual NAT2 slow allele frequencies in HIV patients is reported [Articles:11186133, 12580987, 12043950, 11191886]. A significant association with risk of co-trimoxazole-induced cutaneous reactions was however seen in AIDS patients with a combined NAT2 slow acetylator and GSTM1 null/null genotype [Article:11191886]. Using dapsone or caffeine as a probe drug, no association with slow acetylator phenotype and co-trimoxazole hypersensitivity is observed in HIV patients [Articles:12580987, 12043950, 8689813, 11191886] though one study reports HIV patients who experienced co-trimoxazole hypersensitivity were significantly more likely to have a slow acetylator phenotype than patients who did not experience toxicity [Article:8031511]. Meta-analyses show no significant difference in the frequency of slow acetylator phenotype (combining 4 studies) or genotype (combining 3 studies) in HIV patients with or without hypersensitivity to co-trimoxazole [Articles:12580987, 11186133].
It should be noted that discordance between NAT2 acetylator genotype and acetylator phenotype has been reported in HIV patients [Articles:11191886, 12043950, 12580987, 11191886]. Lower NAT2 activity has been observed in HIV-infected subjects compared to uninfected subjects [Articles:20084375, 18680474]. Genotyping may also be a factor influencing this discrepancy. In one study, discrepancy between genotype and phenotype (as measured by dapsone as a probe drug) in 8 patients could be resolved in half of the cases by sequencing for other variants, the others were slow genotypes with a borderline rapid phenotype - highlighting the importance of looking at variation across the NAT2 gene rather than a handful of variants [Article:12580987].
2. Cardiovascular and hematology agents
Hydralazine is a vasodilator used to treat hypertension [Articles:344023, 21896152]. More recently, due to its epigenetic effects, one group has investigated its use in combination with valproic acid in clinical trials with the hypothesis of reducing tumor resistance and increasing anti-cancer chemotherapy efficacy [Articles:17761710, 17183730, 22427797]. Its beneficial epigenetic effects in cancer cells are thought to be as an inhibitor of DNA methyltransferase (DNMT) enzymes in order to reactivate tumor suppressor genes silenced by DNA methylation [Article:19072646], and may also inhibit histone methyltransferase activity [Article:22427797] and histone acetyltransferases [Article:17156885]. Hydralazine is thought to be metabolized by two pathways, both of which involve acetylation [Article:2860675]. One is via direct acetylation, forming the metabolite 3-methyl-s-triazolo(3,4-a)-phthalazine (MTP), and 3-OH-MTP [Articles:2860675, 7587931]. Another is via oxidation to form an unstable intermediate compound that is acetylated to form N-acetylhydrazinophthalazine (NAcHPZ) [Article:2860675].
Acetylation status has been associated with PK parameters of hydralazine. After oral dose, rapid acetylators display lower hydralazine plasma concentrations and area under the concentration-time curve (but no real difference in drug half life) compared to slow acetylators [Articles:344023, 2860675, 21781652]. MTP/ hydralazine ratio can be used to divide a population into slow and rapid acetylators, with a lower and higher ratio, respectively [Article:1396201]. In one study, patients with a slow acetylator genotype displayed significant reductions in blood pressure measurements at 24 hours before and after hydralazine, whereas significant effects were not observed in rapid or intermediate acetylators [Article:24444407]. Three out of a total of four patients who presented hydralazine-induced adverse reactions had a slow acetylator genotype [Article:24444407]. However, evidence for hydralazine dose adjustment based on acetylator status is not clear. In recent clinical trials in cancer patients, rapid acetylators (according to SMZ-acetylator phenotype) are given more than double the dose of hydralazine than that of slow acetylators. This resulted in similar plasma levels between the two acetylator groups in two studies [Articles:17183730, 21781652]; but significantly higher plasma levels in rapid acetylators in a third study by the same group [Article:17761710]. In a separate study examining blood pressure and cardiac output, using half doses of hydralazine in SMZ-slow acetylators was ineffective at changing peripheral resistance [Article:2244017]. A model incorporating multiple clinical factors including acetylator status may better predict dose required for better response to hydralazine [Article:2231320]. The FDA-approved BiDil® (contains isosorbide dinitrate and hydralazine hydrochloride) is indicated for the treatment of heart failure in self-identified Black patients (though the genetics behind the mode of efficacy is to our knowledge currently unknown), and the drug label contains information regarding acetylation status explaining that rapid acetylators have lower exposure to the drug; however changes to dosing according to this are not mentioned.
Hydralazine treatment is associated with an increased risk of systemic lupus erythematosus (SLE) [Articles:20840450, 21513360], and this has been associated with acetylator status, though again this lacks clear evidence (discussed in [Article:4029245]). Acetylator status may be related to disease severity, with an increased number of lesions seen in slow SMZ acetylators with discoid LE and SLE [Article:4029245]. Studies using bacterial strains suggest that hydralazine is detoxified by acetylation to MTP [Article:7587931]. Other studies also suggest that drug-induced toxic side effects are likely due to hydralazine itself rather than its metabolites - hydralazine and INH both inhibit complement component C4, whereas MTP and N-acetyl INH have little inhibitory effect - inhibitory effects on the complement system may contribute to impaired clearance of immune complexes and thus to SLE [Articles:6147500, 20005073, 24467436]. Development of anti-nuclear antibody positivity in patients treated with hydralazine has been reported to be more likely and more rapid in slow acetylators compared to rapid acetylators, with occurrence of lupus more likely in slow acetylators [Articles:344023, 2860675]. However, further evidence and studies determining the genetic variants behind this association are required. Another potential mechanism behind hydralazine-induced lupus is the reduction of B cell receptor gene rearrangements required for self-tolerance shown in mice models, and transfer of hydralazine treated bone marrow B cells to naive mice caused autoantibody production compared to vehicle control transferred cells [Article:17404230]. Slow acetylators may have reduced clearance of hydralazine and thus higher repression of this mechanism compared to rapid acetylators, but again this requires investigation. Another theory suggests hydralazine-derivative (including todralazine and INH) -induced liver injury is due to inhibition of histone acetylation (carried out by histone acetyltransferase (HAT) enzymes), affecting transcription and inhibiting proliferation and thus impairing liver regeneration after hepatotoxicity has occurred [Article:17156885]. This is supported by slow acetylator mouse models in which todralazine treatment did not induce liver failure on its own; however in mice with anti-CD95 induced liver injury, it resulted in mortality, smaller livers and impaired histone acetylation compared to controls despite similar alanine transaminase (ALT) levels [Article:17156885]. The role of HATs, their cofactors, and histone acetylation in liver regeneration after toxic injury has been shown in other studies [Articles:21319192, 21763259]. This may be another contributing factor to drug-induced liver injury that affects association with NAT2 genotype. Toxicity of hydralazine and related compounds is likely a combination of formation of reactive species, triggering of immune responses/ autoimmunity, and epigenetic effects.
3. Pain, anti-inflammatory and immunomodulating agents
Sulfasalazine is indicated for the treatment of ulcerative colitis, Crohn's disease and as a second-line treatment for arthritis (DrugBank) [Article:15752]. It is a combination of 5-aminosalicyclic acid and sulfapyridine linked together by an azo bond [Articles:2860675, 15752]. Gut bacteria split the bond, a mechanism thought to deliver the two compounds at higher concentrations to the colon than if administered alone [Articles:15752, 4402374]. The effective derivative of sulfasalazine is considered to be 5-aminosalicylic acid, the majority of which remains in the colon where it is subject to N-acetylation by NAT1 [Article:2860675] (DrugBank). The second derivative, sulfapyridine, is readily absorbed and converted to N-acetyl-sulfapyridine, a process influenced by NAT2 acetylator status [Articles:2860675, 15752].
Sulfasalazine PK is not influenced by NAT2 polymorphisms; however, metabolism of sulfapyridine to N-acetyl-sulfapyridine is significantly reduced in slow acetylators (carriers of two variant alleles NAT2*5B, *6A, *7B or *5, *6 and *7) compared to both intermediate (one variant and one NAT2*4 allele) and rapid acetylators (NAT2*4/*4) [Articles:18167504, 19560446]. Slow acetylators have higher concentrations and elimination half-life of sulfapyridine (based on genotyping NAT2 SNPs rs1041983, rs1801280, rs1799929, rs1799930, rs1799931) [Article:20040334]. Plotting of the metabolic ratio N-acetyl-sulfapyridine/ sulfapyridine against NAT2 genotype gives two distinct groups: rapid and slow acetylators [Article:20040334]. There may therefore be an association between increased risk of sulfasalazine-induced toxicity and higher concentrations of sulfapyridine observed in slow acetylators [Articles:2860675, 15752]. A prospective study in Japan of female rheumatoid arthritis (RA) patients treated with sulfasalazine identified 4 patients who had adverse events in a one year period - none had the NAT2*4 allele, each carrying two variant alleles [Article:18398952].
Paraxanthine, a metabolite of caffeine, can undergo acetylation by NAT2 to form 5-acetylamino-6-formylamino-3-methyluracil (AFMU) (see PharmGKB Caffeine Pathway, Pharmacokinetics) [Article:22293536]. Caffeine can be used as a non-toxic probe drug in vivo for predicting acetylator phenotype; by measuring metabolite ratio AFMU/1-methyl xanthine (1X) in urine after caffeine consumption, a bi- or tri-modal pattern in a given population is observed [Articles:6721992, 2312737, 8689813]. AFMU/AFMU+1X+1-methyluric acid (1U), AFMU+5-acetylamino-6-amino-3-methyluracil (AAMU)/AFMU+AAMU+1X+1U or AAMU/ AAMU+1X+1U metabolite ratios can also be used to determine acetylator phenotype [Articles:17221922, 22105431, 20801937, 14747882, 24306330]. Variability in NAT2 activity (as determined by caffeine AFMU/AFMU+1X+1U ratio) between different populations exists - significantly higher NAT2 activity is observed in Koreans compared to Swedes, and this may be due to a higher proportion of the NAT2*4 rapid allele in Koreans and the higher frequency of slow acetylator genotype in Swedes [Article:22105431]. Some studies report good concordance between acetylator phenotype determined by caffeine metabolite ratio and NAT2 genotype [Articles:17011540, 14747882]; however others show discordance [Articles:11191886, 20801937, 15558239, 11214777, 9333101, 7668286]. These discrepancies may be due to differences in sample collection and handling, laboratory techniques and conditions, genotyping method, differences in assignment of slow/intermediate/rapid to genotypes based on NAT2 allele combinations, whether heterozygotes are analyzed independently, as well as other genetic, disease state, environmental factors or use of drugs that could affect the caffeine metabolism pathway (as discussed in [Articles:15558239, 18680467, 8781741, 8866914, 12580991, 9333101]). In one study, up to 54% of the variation in acetylation activity determined by caffeine test could be explained by NAT2 genotype (homozygous wildtype, homozygous variant or heterozygous determined by PCR-RFLP), though phenotype variation was seen with homozygous wildtype [Article:8781741].
Cancer: NAT1 and NAT2 association with risk, treatment responses, treatment resistance and as drug targets
Due to their role in the activation or deactivation of xenobiotics, the NAT1 and NAT2 enzymes have been implicated in chemical carcinogenesis pathways. Polymorphisms in the NAT1 and NAT2 genes have therefore been investigated for an association with cancer risk, though findings are inconsistent, likely due to the complex nature of cancer etiology and the multiple factors that contribute to susceptibility.
For studies examining the risk of bladder cancer, some report a significant association with NAT2 slow acetylator genotype/ phenotype (e.g. [Article:22961351]), others do not after adjusting for multiple factors [Articles:24221535, 24092628]. Recent GWAS meta-analyses reveal multiple risk loci, including NAT2 [Article:24163127]. A meta-analysis of cases in the general population (n=5594) showed a significant association between NAT2 slow acetylation with risk of bladder cancer (OR=1.37, C.I.=1.22-1.54, p=2x10-7) [Article:17510073]. The rs1495741 AA genotype (located downstream of the NAT2 gene and associated with the slow acetylator status) was significantly associated with increased risk of bladder cancer in Europeans compared to those with AG or GG genotype [Article:20739907], and a GWAS meta-analysis consisting of 12,270 cases and 55,059 controls confirmed the association with the A risk allele, along with numerous other SNPs at other loci that contribute to risk [Article:24163127]. Furthermore, both an additive and multiplicative association was shown between smoking and rs1495741 allele A with risk of bladder cancer [Article:24163127]. This GWAS meta-analysis study did not identify risk alleles associated with NAT1, and a meta-analysis of 11 studies (n=3311 cases, n=3906 controls) found no association between bladder cancer and the NAT1*10 allele [Article:23569127]. However, NAT1*14A has been associated with increased risk of bladder cancer in Lebanese men [Articles:24319536, 23803105, 22956951].
Associations between NAT1/2 variants and susceptibly to other cancers also lacks clarity or require further study [Articles:18852012, 22090474, 16257833, 18680472]. For example, NAT2 slow acetylator genotype may be a small, low penetrance risk factor for head and neck cancer [Article:24338712]. Mixed results are reported for NAT2 genotype and risk of breast cancer [Articles:23628324, 24023296] and esophageal cancer [Articles:17661210, 19766908, 24586291]. The InterLymph Consortium found no association between NAT2 phenotype (based on genotype, 4421 cases, 4095 controls) or NAT1*10 (1528 cases, 1586 controls) and risk of non-hodgkin lymphoma [Article:23160945].
Gene-environment interactions for cancer risk have been reported in an attempt to identify risk factors [Article:18680472]. For example, individuals with a NAT1 rapid acetylator genotype (defined as homozygous for alleles NAT1*10, *11, or these alleles in combination with NAT1*3, *4), and AHR rs2066853 genotype GA or AA, and high meat consumption were found to have an increased risk of concurrent adenomatous and hyperplastic colorectal polyps [Article:18268115]. Conversely, meta-analyses show no statistically significant interaction between NAT1 acetylator phenotype and meat intake (2 studies), or NAT2 acetylator phenotype and meat intake (3 studies), with relation to risk of colorectal cancer [Article:23216531], though this may be due to low penetrance and the need to include multiple genetic risk factors.
As well as combinatorial environmental/ genetic factors, reaction context is also an important consideration - examining the site of action and specific reaction by NAT1/ NAT2 may make these associations clearer and more consistent. For example, O-acetylation by NAT1 can result in the formation of nitrenium ions from the unstable N-acetoxyarylamine which can react with DNA to cause mutations, whereas N-acetylation by NAT1 detoxifies aromatic amines [Articles:19379125, 22114069]. Similarly, O-acetylation of N-hydroxy-heterocyclic amine carcinogens by NAT2 in the colon can explain the association between rapid acetylator phenotype and colorectal cancer risk in those who consume well-done meat, whereas association with slow acetylator phenotype and bladder cancer in smokers or those exposed to chemical dyes can be explained by N-acetylation competing with N-hydroxylation by cytochrome P450 enzymes that produce aromatic amine carcinogens in the liver [Article:19379125]. N-acetylation of an aryldiamine (for example benzidine) could increase risk of bladder cancer due to enhancement of N-hydroxylation, whereas as N-acetylation of an arylmonoamine may have the opposite effect [Articles:19379125, 17510073]. It should also always be kept in mind that "slow" and "rapid" acetylator phenotype is not homogenous, and that if the underlying genetic polymorphisms affect enzyme-substrate affinity, then the resulting association may only be seen with some drugs/ chemicals and exposure levels [Article:19379125]. NAT1 activity is influenced by substrate-dependent down-regulation, the redox state of cells, and epigenetic regulation [Article:22090474], thus these may contribute to the lack of consistency seen between a direct association between NAT1 genotype and cancer risk, along with interacting environmental factors, other genetic polymorphisms, inconsistencies in allele-phenotype definitions or genotyping methods. For instance, attributing the rapid acetylation phenotype to the NAT1*10 and *11 alleles remains an issue of controversy among investigators and the phenotypic effects of many NAT1 polymorphisms (especially those in the 3' untranslated region of the gene) are still not well understood [Article:19379125]. Cell-specific expression of alleles, alternative NAT1 transcripts driven by different promoters or alternative polyadenylation site use may also be a factor, or if SNPs are missed in genotyping (for example misclassification of NAT1*10B for NAT1*10 [Articles:19379125, 22114069]).
Overexpression of NAT1 is a common finding in estrogen receptor positive breast tumors [Articles:18642144, 24467436]. Cells over-expressing NAT1 display resistance to etoposide in vitro [Article:14517345], and thus NAT1 activity may have implications in response to anti-cancer therapy - polymorphisms in the NAT1 gene that result in changes in enzyme activity could affect drug response, though this needs to be investigated. These, and studies that show an association between increased NAT1 expression/ activity and cancer cell proliferation, support the use of specific NAT1 probes as potential diagnostic tools and the development of direct NAT1 inhibitors as potential leads for cancer therapeutics [Articles:20170182, 22776642, 22090474, 21347396, 20100460, 19059786, 14517345, 24467436]. Though not their primary target, several current chemotherapeutics have been shown to inhibit NAT1 or N-acetyltransferase activity in vitro in human cancer cells: cisplatin [Article:18310302] and tamoxifen [Articles:12889515, 17564319].
Amonafide has anti-cancer properties but is no longer in clinical development due to failing to reach phase III clinical trial primary end points [Article:22272701]. The drug displayed variable and unpredictable toxic effects [Article:11259359]. NAT2 phenotype was one of the underlying genetic factors contributing to variation in myelosuppression severity; rapid acetylators (determined by caffeine test) were susceptible to greater toxicity and counter-intuitively displayed higher plasma concentrations of amonafide. This was thought to be due to production of the metabolite N-acetyl amonafide which inhibits the oxidation of amonafide by CYP1A2 [Articles:11259359, 1934870, 7884434]. Thus, higher and lower doses from the standard dosage were recommended in slow and rapid acetylators, respectively, and a pharmacodynamic model incorporating acetylator phenotype, gender and pre-treatment white blood cell count was developed [Articles:8485716, 8845865]. The story from this drug highlighted the importance of genetic influence on both drug pharmacokinetics and pharmacodynamics [Articles:11259359, 8845865].
NAT2 polymorphisms/ acetylator phenotype has been associated with risk of other complex multifactorial diseases (including asthma, Parkinson¿s Disease and diabetes), however the associations are inconclusive and further discussion of these is beyond the scope of this review [Articles:18680473, 18680475].
NAT1 and NAT2 are polymorphic enzymes with important roles in the deactivation or activation of numerous xenobiotics in humans. Due to expression of the isoenzyme in the liver, the genetic variants of NAT2 have primarily been associated with drug metabolism, response and toxicity. NAT2 genotype confers a slow, intermediate or rapid acetylation phenotype, resulting in differences in drug metabolic rates and susceptibility to drug toxicity. However, studies show inconsistencies for which NAT2 and NAT1 variants are genotyped and in the pooling of variants into phenotype groups, thus these factors along with how a patient's disease phenotype is defined, environmental factors, drug-drug interactions, and acetylation reaction context may contribute to the contradictory evidence for some pharmacogenetic and disease associations. Further studies are required to help determine whether genotyping of NAT2 is clinically useful for determining a patient's dosage for efficacy of treatment and to avoid drug toxicity.
|Citation||PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, Boukouvala Sotiria, Aklillu Eleni, Hein David W, Altman Russ B, Klein Teri E.|
Submitted by Ellen M. McDonagh, Sotiria Boukouvala, Eleni Aklillu, David W. Hein, Russ B. Altman, Teri E. Klein, Ph.D. (Aug 2013)
|Variant Summaries||rs1041983, rs1208, rs1495741, rs1799929, rs1799930, rs1799931, rs1801279, rs1801280, rs4271002, rs4646244|
NAT2 haplotypes are from the Arylamine N-acetyltransferase Gene Nomenclature Committee; 3/10/2014.
- NAT2*4 (reference haplotype)
All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Benzodiazepine Pathway, Pharmacokinetics
Diagrammatic representation of the metabolism of different benzodiazepine drugs by candidate genes.
Busulfan Pathway, Pharmacodynamics
Schematic representation of mechanism of action of busulfan and its metabolism.
Caffeine Pathway, Pharmacokinetics
Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
Publications related to NAT2: 176
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]